| Business Summary | | Micro
Therapeutics,
Inc.
(MTI)
develops,
manufactures
and
markets
minimally
invasive
medical
devices
for
the
diagnosis
and
treatment
of
vascular
disease.
MTI
focuses
its
efforts
in
two
under-served
markets,
the
treatment
of
neurovascular
disorders
of
the
brain
associated
with
stroke
and
the
treatment
of
peripheral
vascular
disease,
including
blood
clot
therapy
in
hemodialysis
access
grafts,
arteries
and
veins.
The
Company's
objective
is
to
provide
physicians
with
new
interventional
treatment
alternatives,
which
improve
outcomes,
reduce
costs,
shorten
procedure
times,
reduce
drug
usage
and
allow
access
to
difficult-to-reach
anatomical
locations.
The
Company
currently
markets
more
than
130
products
for
the
treatment
of
neuro
and
peripheral
vascular
disease.
The
primary
users
of
MTI's
products
are
interventional
radiologists
and
neuroradiologists. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | MTIX
develops,
manufactures,
and
markets
minimally
invasive
medical
devices
to
diagnose
and
treat
vascular
diseases.
MTIX
treatments
serve
two
markets:
neuro
vascular
disorders
and
peripheral
vascular
diseases.
For
the
six
months
ended
6/01,
revenues
totalled
$4.8
million,
up
from
$2.3
million.
Net
loss
rose
34%
to
$7
million.
Revenues
reflect
higher
sales
of
micro
catheter,
access
and
delivery
products.
Higher
loss
reflects
costs
associated
with
the
sales
force. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| George Wallace, 42 Chairman | $342K | John Rush, 42 Pres,
CEO, Director | 187K | Harold Hurwitz, 49 CFO | 190K | William McLain, 51 VP-Operations | 178K | Kevin Daly, 44 VP,
Regulatory Affairs and Quality Assurance | 178K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|